Comparative Pharmacology
Head-to-head clinical analysis: LOW QUEL versus NORLESTRIN 28 1 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOW QUEL versus NORLESTRIN 28 1 50.
LOW-QUEL vs NORLESTRIN 28 1/50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Low-Quel is a combination product containing an opioid agonist and a non-opioid analgesic. The opioid component acts on mu-opioid receptors in the central nervous system to alter pain perception, while the non-opioid component inhibits cyclooxygenase enzymes, reducing prostaglandin synthesis and providing additive analgesia.
Combination estrogen-progestin oral contraceptive; suppresses gonadotropin release via negative feedback on pituitary, inhibits ovulation, thickens cervical mucus, alters endometrial receptivity.
10 mg orally twice daily; not to exceed 20 mg/day.
One tablet orally once daily, each containing norethindrone 1 mg and ethinyl estradiol 50 mcg.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours in healthy adults; increases to 20-24 hours in hepatic impairment and 18-22 hours in moderate renal impairment (CrCl 30-50 mL/min).
Norethindrone: 8 hours; ethinyl estradiol: 12-15 hours; steady state achieved within 5-10 days.
Renal excretion of unchanged drug accounts for 60-70% of elimination; hepatic metabolism accounts for 20-30% (primarily CYP3A4); biliary/fecal excretion of metabolites accounts for <10%.
Norethindrone: 40% renal, 60% fecal; ethinyl estradiol: 40% renal, 60% fecal.
Category C
Category C
Oral Contraceptive
Oral Contraceptive